Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Atrial fibrillation (stroke prevention) - rivaroxaban: review decision April 2013 information

Atrial fibrillation (stroke prevention) - rivaroxaban: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 195 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: review proposal - February 2013 information

Appendix A: provisional matrix of stakeholders (PDF 107 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 632 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: equality impact assessment - guidance development (PDF 86 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: final appraisal determination information

Atrial fibrillation (stroke prevention) - rivaroxaban: final appraisal determination document (PDF 275 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 610 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: consultee and commentator comments on the ACD

Atrial fibrillation (stroke prevention) - rivaroxaban: AntiCoagulation Europe (PDF 51 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance (PDF 373 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Atrial Fibrillation Association (PDF 682 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer (PDF 610 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Boehringer Ingelheim (PDF 596 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer (PDF 174 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: British Association of Stroke Physicians (PDF 34 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Commissioning Support Appraisal Service (PDF 359 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Department of Health (PDF 4.6 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Medicines and Healthcare Products Regulatory Agency (PDF 5.3 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: National Clinical Guidelines Centre (PDF 41 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire cluster (PDF 5.5 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing (PDF 59 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Pathologists and BSH (PDF 94 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: The British Cardiovascular Intervention Society (PDF 3.7 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: The Stroke Association (PDF 38 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: expert comments on the ACD

Atrial fibrillation (stroke prevention) - rivaroxaban: Potter (PDF 25 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Sayers (PDF 97 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: comments on the ACD received from the public through the NICE website (PDF 309 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: ERG's response to Bayer's comments on the ACD

Atrial fibrillation (stroke prevention) - rivaroxaban: ERG response (PDF 468 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: additional report (PDF 170 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: second additional report (PDF 269 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consultation

Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consultation document information

Atrial fibrillation (stroke prevention) - rivaroxaban: evaluation report

Atrial fibrillation (stroke prevention) - rivaroxaban: pre-meeting briefing (PDF 344 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report

Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report (PDF 2.2 MB)

Atrial fibrillation (stroke prevention) - rivaroxaban: ERG report erratum (PDF 437 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report - factual accuracy check (PDF 214 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer (PDF 2.17 MB)

Atrial fibrillation (stroke prevention) - rivaroxaban: clarification

Atrial fibrillation (stroke prevention) - rivaroxaban: NICE clarification letter (PDF 471 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: manufacturer response to the NICE clarification letter (PDF 714 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: eligibility criteria (PDF 193 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: patient group, professional group and NHS organisation submission statements

Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance (PDF 85 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Atrial Fibrillation Association (AFA Affiliated) (PDF 85 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Heart Rhythm UK (PDF 84 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire (PDF 70 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing (PDF 4.9 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Pathologists and BSH (PDF 189 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: expert written personal statements

Atrial fibrillation (stroke prevention) - rivaroxaban: Eaton (PDF 98 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Jerrome (PDF 93 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Maclean (PDF 96 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Potter (PDF 144 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: Sayers (PDF 129 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: appendix A - final matrix (PDF 59 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: appendix B - final scope (PDF 38 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: appendix C - response to consultee and commentator comments on the draft remit and draft scope (pre-referral) (PDF 221 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: appendix D - response to consultee and commentator comments on the provisional matrix of consultees and commentators (PDF 15 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban: draft scope for consultation (pre-referral) - July 2010 (PDF 30 KB)

Atrial fibrillation (stroke prevention) - rivaroxaban; provisional matrix (pre-referral) - July 2010 (PDF 31 KB)